Review



mirna microarray chip  (LC Sciences)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    LC Sciences mirna microarray chip
    A workflow of the experimental design was showed (A) . Cluster analysis in chemoresistant (C) and chemosensitive (H) breast cancer tissues (B) . Hierarchical clustering of 33 <t>miRNAs</t> differentially expressed in 20 breast cancer patients, including miR-638, miR-23a-3p, miR-23b-3p, miR-200c-3p, miR-214-3p and miR-451a. Red: up-regulated; green: down-regulated miRNAs in the chemoresistant group. Samples are in columns; miRNAs are in rows. Expression values ranged from −3 to +3 log2. (C) 33 miRNAs are significantly expressed between chemoresistant (G1) and chemosensitive (G2) groups. Mean fold-change of chemosensitive vs. chemoresistant groups at log2 (G2/G1). qRT-PCR results showed that miR-23a-3p, miR-23b-3p, miR-200c-3p, and miR-214-3p were significantly up-regulated, and miR-638 and miR-451a were significantly downregulated in the chemoresistant group in the training set [ (D) ; p = 0.0259; 0.0379; 0.0354; 0.0367; 0.001; 0.002], internal testing set [ (E) ; p = 0.0292; 0.0486; 0.0283; 0.118; 0.0036; 0.013], in the independent set [ (F) ; p = 0.0026; 0.0195; 0.0077; 0.0162; 0.0036; 0.0209] and combined set (including training set, internal testing set and the independent set; (G) : p = 0.0015; 0.0003; 0.0037; 0.003; 0.001; 0.001). The data was represented as the mean and SE (standard error).
    Mirna Microarray Chip, supplied by LC Sciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mirna+microarray+chip+screening/pmc08262148-151-1-24?v=LC+Sciences
    Average 90 stars, based on 1 article reviews
    mirna microarray chip - by Bioz Stars, 2026-08
    90/100 stars

    Images

    1) Product Images from "Identification of miRNA Signature in Breast Cancer to Predict Neoadjuvant Chemotherapy Response"

    Article Title: Identification of miRNA Signature in Breast Cancer to Predict Neoadjuvant Chemotherapy Response

    Journal: Pathology and Oncology Research

    doi: 10.3389/pore.2021.1609753

    A workflow of the experimental design was showed (A) . Cluster analysis in chemoresistant (C) and chemosensitive (H) breast cancer tissues (B) . Hierarchical clustering of 33 miRNAs differentially expressed in 20 breast cancer patients, including miR-638, miR-23a-3p, miR-23b-3p, miR-200c-3p, miR-214-3p and miR-451a. Red: up-regulated; green: down-regulated miRNAs in the chemoresistant group. Samples are in columns; miRNAs are in rows. Expression values ranged from −3 to +3 log2. (C) 33 miRNAs are significantly expressed between chemoresistant (G1) and chemosensitive (G2) groups. Mean fold-change of chemosensitive vs. chemoresistant groups at log2 (G2/G1). qRT-PCR results showed that miR-23a-3p, miR-23b-3p, miR-200c-3p, and miR-214-3p were significantly up-regulated, and miR-638 and miR-451a were significantly downregulated in the chemoresistant group in the training set [ (D) ; p = 0.0259; 0.0379; 0.0354; 0.0367; 0.001; 0.002], internal testing set [ (E) ; p = 0.0292; 0.0486; 0.0283; 0.118; 0.0036; 0.013], in the independent set [ (F) ; p = 0.0026; 0.0195; 0.0077; 0.0162; 0.0036; 0.0209] and combined set (including training set, internal testing set and the independent set; (G) : p = 0.0015; 0.0003; 0.0037; 0.003; 0.001; 0.001). The data was represented as the mean and SE (standard error).
    Figure Legend Snippet: A workflow of the experimental design was showed (A) . Cluster analysis in chemoresistant (C) and chemosensitive (H) breast cancer tissues (B) . Hierarchical clustering of 33 miRNAs differentially expressed in 20 breast cancer patients, including miR-638, miR-23a-3p, miR-23b-3p, miR-200c-3p, miR-214-3p and miR-451a. Red: up-regulated; green: down-regulated miRNAs in the chemoresistant group. Samples are in columns; miRNAs are in rows. Expression values ranged from −3 to +3 log2. (C) 33 miRNAs are significantly expressed between chemoresistant (G1) and chemosensitive (G2) groups. Mean fold-change of chemosensitive vs. chemoresistant groups at log2 (G2/G1). qRT-PCR results showed that miR-23a-3p, miR-23b-3p, miR-200c-3p, and miR-214-3p were significantly up-regulated, and miR-638 and miR-451a were significantly downregulated in the chemoresistant group in the training set [ (D) ; p = 0.0259; 0.0379; 0.0354; 0.0367; 0.001; 0.002], internal testing set [ (E) ; p = 0.0292; 0.0486; 0.0283; 0.118; 0.0036; 0.013], in the independent set [ (F) ; p = 0.0026; 0.0195; 0.0077; 0.0162; 0.0036; 0.0209] and combined set (including training set, internal testing set and the independent set; (G) : p = 0.0015; 0.0003; 0.0037; 0.003; 0.001; 0.001). The data was represented as the mean and SE (standard error).

    Techniques Used: Expressing, Quantitative RT-PCR

    Association between five deregulated miRNAs and endocrine features or chemotherapy drugs. miR-451a was less expressed in ER-negative cases compared to ER-positive cases [ (A) ; p = 0.0296]. miR-23a expression was greater in PR-positive cases compared to PR-negative cases [ (B) ; p = 0.0367]. miR-638 and miR-451a were down-regulated in HER2-negative cases, compared with HER2-positive cases [ (C, D) ; p = 0.0219; 0.0117]. Compared with Ki67-low cases, more expression of miR-638 and miR-200c-3p were observed in Ki67-high cases [ (E, F) ; p = 0.017; 0.0233]. miR-214-3p expression was increased in p53-positive vs. p53-negative cases [ (G) ; p = 0.0213]. miR-23a-3p expression in A and T groups were higher than in the AT group [ (H) ; p = 0.0393; 0.0430]. Upregulated miR-200c-3p was observed in A group, compared with T and AT groups [ (I) ; p = 0.0177, 0.0361]. miR-214-3p was upregulated in T group, compared with A and AT groups [ (K) ; p = 0.0254, 0.0373]. Reduced expression of miR-638 occurred in the A group, compared with T and AT groups [ (J) ; p = 0.019, 0.0162]. Significantly step-upregulated expression of miR-451a occurred in A, T and AT groups (L) . Significant difference of miR-451a expression was observed between A and T groups ( p = 0.0454), between A and AT groups ( p = 0.0177), between T and AT groups ( p = 0.0494). The data was represented as the mean and SE. ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; A, anthracycline; T, taxol; AT, anthracycline and taxol combination. SE, standard error.
    Figure Legend Snippet: Association between five deregulated miRNAs and endocrine features or chemotherapy drugs. miR-451a was less expressed in ER-negative cases compared to ER-positive cases [ (A) ; p = 0.0296]. miR-23a expression was greater in PR-positive cases compared to PR-negative cases [ (B) ; p = 0.0367]. miR-638 and miR-451a were down-regulated in HER2-negative cases, compared with HER2-positive cases [ (C, D) ; p = 0.0219; 0.0117]. Compared with Ki67-low cases, more expression of miR-638 and miR-200c-3p were observed in Ki67-high cases [ (E, F) ; p = 0.017; 0.0233]. miR-214-3p expression was increased in p53-positive vs. p53-negative cases [ (G) ; p = 0.0213]. miR-23a-3p expression in A and T groups were higher than in the AT group [ (H) ; p = 0.0393; 0.0430]. Upregulated miR-200c-3p was observed in A group, compared with T and AT groups [ (I) ; p = 0.0177, 0.0361]. miR-214-3p was upregulated in T group, compared with A and AT groups [ (K) ; p = 0.0254, 0.0373]. Reduced expression of miR-638 occurred in the A group, compared with T and AT groups [ (J) ; p = 0.019, 0.0162]. Significantly step-upregulated expression of miR-451a occurred in A, T and AT groups (L) . Significant difference of miR-451a expression was observed between A and T groups ( p = 0.0454), between A and AT groups ( p = 0.0177), between T and AT groups ( p = 0.0494). The data was represented as the mean and SE. ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; A, anthracycline; T, taxol; AT, anthracycline and taxol combination. SE, standard error.

    Techniques Used: Expressing

    Risk scores according to five-miRNA signatures and ROC curves in training, internal testing and independent sets. ROC and AUCs of single miRNA alone and five-miRNA signature from the training (A) , internal testing (B) , and independent sets (C) . Risk scores for patients were calculated by risk scores based on a five-miRNA signature in the training (D) , internal testing. (E) and independent sets (F) .
    Figure Legend Snippet: Risk scores according to five-miRNA signatures and ROC curves in training, internal testing and independent sets. ROC and AUCs of single miRNA alone and five-miRNA signature from the training (A) , internal testing (B) , and independent sets (C) . Risk scores for patients were calculated by risk scores based on a five-miRNA signature in the training (D) , internal testing. (E) and independent sets (F) .

    Techniques Used:

    GO and KEGG analysis of predicted targets of five miRNAs. Data show that genes were enriched in biological processes of signal transduction. (A) ; eight known canonical cancer-associated pathways were predicted by KEGG. (B) , including the p53 signaling pathway, ubiquitin mediated proteolysis, pathways in cancer, the mTOR signaling pathway, the Wnt signaling pathway, regulation of actin cytoskeleton, focal adhesion, and the ErbB signaling pathway. Networks among specific deregulated miRNAs and predicted targets of the classical Wnt signaling pathway. (C) and the MAPK signaling pathway (D) .
    Figure Legend Snippet: GO and KEGG analysis of predicted targets of five miRNAs. Data show that genes were enriched in biological processes of signal transduction. (A) ; eight known canonical cancer-associated pathways were predicted by KEGG. (B) , including the p53 signaling pathway, ubiquitin mediated proteolysis, pathways in cancer, the mTOR signaling pathway, the Wnt signaling pathway, regulation of actin cytoskeleton, focal adhesion, and the ErbB signaling pathway. Networks among specific deregulated miRNAs and predicted targets of the classical Wnt signaling pathway. (C) and the MAPK signaling pathway (D) .

    Techniques Used: Transduction, Ubiquitin Proteomics



    Similar Products

    mirna microarray chip screening  (Annoroad Gene Technology Co Ltd)
    90
    Annoroad Gene Technology Co Ltd mirna microarray chip screening
    Mirna Microarray Chip Screening, supplied by Annoroad Gene Technology Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mirna+microarray+chip+screening/pm36733250-236-101-43?v=Annoroad+Gene+Technology+Co+Ltd
    Average 90 stars, based on 1 article reviews
    mirna microarray chip screening - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier

    Image Search Results